Track Relmada Therapeutics's long-term debt ($0) with charts, peers, and YoY trends.
Get informed when a big investor buys or sells
+ FollowLatest change versus the prior comparable period (same company).
Relmada Therapeutics (RLMD) currently reports a long-term debt of $0 as of March 2026. In the prior-year period, the figure was $0. Use the charts on this page to explore Relmada Therapeutics's long-term debt history and peer comparisons.
Relmada Therapeutics's long-term debt changed from $0 to $0 (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.
Relmada Therapeutics reported $0 in long-term debt as of March 2026. In the prior-year period, the figure was $0. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.
Start with the current long-term debt of $0, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Relmada Therapeutics, and consider following RLMD for alerts when major investors trade the stock.
Relmada Therapeutics is classified in the Consumer Discretionary sector. On long-term debt, it currently shows $0. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Consumer Discretionary are usually more informative than comparing RLMD with unrelated industries.